Disc Medicine, Inc.
NASDAQ:IRON · NASDAQ Global Market
-$0.02 today
Vol 1.25M · Avg 0.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.7%
avg 23.5%
ROIC
-30.6%
avg -4322.6%
ROA
-26.3%
avg -103.7%
Analysis
ROA is currently the strongest return metric at -26.3% versus its period average of -103.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John D. Quisel | Chief Executive Officer, President & Director | $1.26M | — | 55 | $226,064.00 | 0.59% |
Jean Franchi | Chief Financial Officer | $838,980.00 | — | 60 | $64,333.00 | 0.17% |
William Jacob Savage | Chief Medical Officer | $836,840.00 | — | 52 | $81,680.00 | 0.21% |
Pamela Stephenson | Chief Commercial Officer | $832,100.00 | — | 58 | $80,998.00 | 0.21% |
Jonathan Yu | Chief Opearating Officer | $811,560.00 | — | 45 | $54,324.00 | 0.14% |
Donald William Nicholson | Executive Chairman | $170,000.00 | — | 68 | $81,680.00 | 0.21% |
Brian MacDonald | Founder & Chair of Scientific Advisory Board | $88,542.00 | — | 65 | — | — |
Sonia Razzetti | Senior Vice President of Quality | — | — | — | — | — |
Rahul Rajan Kaushik | Chief Technical Officer | — | — | — | $52,173.00 | 0.14% |
Steven Caffé | Chief Regulatory Officer | — | — | 66 | — | — |
Joseph Beaulieu | Senior Vice President of Finance | — | — | 45 | — | — |
Srikanth Venkatraman | Senior Vice President & Head of Chemistry | — | — | — | — | — |
Hua Yang | Senior Vice President & Head of Early Development and Clinical Pharmacology | — | — | — | — | — |
Lisa Amaya Price | Chief Human Resources Officer | — | — | — | — | — |
Rahul Khara | Chief Legal Officer & Secretary | — | — | 44 | $52,173.00 | 0.14% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
89
$110.75M
Net Sentiment
$110.75M
Net selling
Most Active
Bitterman Kevin
53 transactions
1–10 of 89
Analysis
Insiders reported 0 buys worth $0.00 and 89 sells worth $110.75M over the last 12 months. That adds up to net selling of $110.75M. Bitterman Kevin was the most active insider with 53 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.59B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.45B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.38B
Legend Biotech Corporation
NASDAQ:LEGN
$5.32B
Celcuity Inc.
NASDAQ:CELC
$4.19B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.17B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.78B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.71B
Zai Lab Limited
NASDAQ:ZLAB
$2.08B
Ascentage Pharma Group International
NASDAQ:AAPG
$407.64M
Who manages IRON?
Disc Medicine, Inc. (IRON) lists 15 active executives. The top listed executive is Pamela Stephenson, Chief Commercial Officer.
Are IRON insiders buying or selling?
Recent insider activity shows net selling of $131.23M.
Explore More
Continue the stock analysis
Jump to another research area for this company.